ProfileGDS5678 / 1417586_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 67% 66% 66% 70% 64% 65% 67% 67% 69% 67% 67% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0746567
GSM967853U87-EV human glioblastoma xenograft - Control 24.073467
GSM967854U87-EV human glioblastoma xenograft - Control 33.9761866
GSM967855U87-EV human glioblastoma xenograft - Control 44.0471966
GSM967856U87-EV human glioblastoma xenograft - Control 54.3885370
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.884164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9502865
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0528367
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0489567
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3123269
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1030467
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0526167
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0701467
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0635167